All In Biotech

Drug Trial Radar · NCT06693609

Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder

A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants With Social Anxiety Disorder

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

May 8, 2025

Primary completion

Dec 10, 2025

Study completion Dec 10, 2025

Sponsor

Lead sponsor
atai Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
EmpathBio, Inc.
First posted
Nov 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study (protocol number EMP-01-201) will determine the safety and tolerability of a short-term treatment with an oral dosage form of EMP-01 in adult participants with social anxiety disorder (SAD) and will assess exploratory efficacy of repeated doses of EMP-01 versus placebo.

Conditions

  • Social Anxiety Disorder

Interventions

  • EMP-01Drug

    EMP-01 capsules

  • EMP-01 PlaceboDrug

    EMP-01 placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment emergent adverse events, adverse events of special interest and serious adverse events.Time frame: Day 1 to EOS [Day 43]
  2. Incidence of clinically significant abnormalities in physical examinations, vital signs, electrocardiogram parameters, and safety laboratory results.Time frame: Day 1 [post-dose] to Day 57
  3. Columbia-Suicide Severity Rating Scale (C-SSRS) ScoreTime frame: Baseline to Day 57

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • MAC Clinical Research Centre, West Yorkshire

    Leeds, United Kingdom

  • MAC Clinical Research - South Staffordshire

    Bridgetown, Cannock, Staffordshire, United Kingdom

  • MAC Clinical Research - Greater Manchester

    Manchester, Greater Manchester, United Kingdom

  • MAC Clinical Research - Lancashire

    Blackpool, Lancashire, United Kingdom

  • MAC Clinical Research - Merseyside

    Liverpool, Merseyside, United Kingdom

  • MAC Clinical Research - South Yorkshire

    Tankersley, South Yorkshire, United Kingdom

  • MAC Clinical Research - Teesside

    Thornaby, Stockton-on-Tees, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.